SUPN

SUPN

USD

Supernus Pharmaceuticals Inc. Common Stock

$57.000+1.570 (2.832%)

السعر في الوقت الحقيقي

Healthcare
Drug Manufacturers - Specialty & Generic
الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$55.430

الأعلى

$57.400

الأدنى

$54.610

الحجم

4.00M

أساسيات الشركة

القيمة السوقية

3.2B

الصناعة

Drug Manufacturers - Specialty & Generic

البلد

United States

إحصاءات التداول

متوسط الحجم

0.82M

البورصة

NGM

العملة

USD

نطاق 52 أسبوعاً

الأدنى $29.16الحالي $57.000الأعلى $57.65

أخبار ذات صلة

Analyst Upgrades

B of A Securities Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces Price Target of $65

B of A Securities analyst Pavan Patel initiates coverage on Supernus Pharmaceuticals with a Buy rating and announces Price Target of $65.

عرض المزيد
B of A Securities Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces Price Target of $65
Analyst Upgrades

TD Cowen Maintains Buy on Supernus Pharmaceuticals, Raises Price Target to $60

TD Cowen analyst Stacy Ku maintains Supernus Pharmaceuticals with a Buy and raises the price target from $45 to $60.

عرض المزيد
TD Cowen Maintains Buy on Supernus Pharmaceuticals, Raises Price Target to $60
GlobeNewswire

Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

ROCKVILLE, Md., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

عرض المزيد
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
Analyst Upgrades

Piper Sandler Upgrades Supernus Pharmaceuticals to Overweight, Raises Price Target to $65

Piper Sandler analyst David Amsellem upgrades Supernus Pharmaceuticals from Neutral to Overweight and raises the price target from $40 to $65.

عرض المزيد
Piper Sandler Upgrades Supernus Pharmaceuticals to Overweight, Raises Price Target to $65

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.